Our Mission Statement

HTRS is the leading North American professional society dedicated to research, mentoring, workforce development, and continuing medical education for physicians, investigators, and all health care professionals interested in advancing care for people with hemostatic and thrombotic disorders.

Please join us!  Check out our membership levels and benefits: CLICK HERE

 

World Thrombosis Day is Sunday, October 13, 2019.

To get involved and/or stay informed, see article below right.

 

 

Residents and/or fellows now may apply to participate in the upcoming 2019 Pre-ASH HTRS Trainee Workshop: “Building a Career in Hemostasis and Thrombosis.” 

This Workshop will take place at the Loews Sapphire Falls Resort in Orlando, Florida, on December 4-5, 2019, prior to the American Society of Hematology's Annual Meeting & Exposition. 

APPLY TODAY!

Further, 2019 Pre-ASH Trainee Workshop applications are due on or before October 18, 2019, 11:59 pm ET.  Any questions, please email [email protected].

Research

Read more

Mentoring

Read more

Workforce Development

Read more

Continuing Education

Read more

Events

 

 


HTRS Member Spotlight Q&A: HTRS 2019 Lifetime Achievement Awardees Drs. M. Elaine Eyster and Victor Blanchette Receive Distinction


To honor their outstanding career contributions to the field of hemostasis and thrombosis, Drs. M. Elaine Eyster and Victor Blanchette each received a 2019 HTRS Lifetime Achievement Award, bestowed at the HTRS/NASTH 2019 Scientific Symposium in New Orleans, LA this past May. Dr. Victor S. Blanchette, MD (pictured left), is Medical Director of the Pediatric Thrombosis and Hemostasis Program at the Hospital for Sick Children, Toronto, and Professor of Pediatrics at the University of Toronto, Canada.  Dr. M. Elaine Eyster, MD, FACP (pictured above), is Distinguished Professor of Medicine at the Penn State Health Milton S. Hershey Medical Center and Penn State College of Medicine.  Get to know them better...click below!

DR. M. ELAINE EYSTER Q&A: CLICK HERE

DR. BLANCHETTE Q&A: CLICK HERE

 

Special Tribute to Joan Cox Gill, MD

In honor of Joan Cox Gill, MD, HTRS co-founder and longtime Board Treasurer, an Eastern red bud tree was planted outside Versiti's Comprehensive Center for Bleeding Disorders (CCBD) on August 12, 2019. Family, friends, and Versiti colleagues gathered to honor Dr. Gill's legacy and her years of dedicated service to the hemostasis/thrombosis community.  Picnic tables will be added to the area around the tree, creating an outdoor space for CCBD staff to enjoy for years to come.

Special thanks to the following HTRS members for making this wonderful tribute possible: Lynn Malec, MD, MSc, current HTRS Treasurer and CCBD Medical Director; CCBD Manager Tiffini Mueller, RN, BSN; and Gilbert C. White, II, MD, MS, Versiti's Executive Vice President of Research and Director of the Versiti Blood Research Institute.

 

Exciting NHLBI News: Blueprint, Strategies and Tools for Future Factor VIII Inhibitor-Related Research

Factor VIII Inhibitor State of the Science Workshop Proceedings have been published in the July 2019 edition of Hemophilia - Volume 24, Issue 4 

For more info, CLICK HERE.

 

Abstracts from 2019 Symposium published in Haemophilia

The Abstracts from the HTRS/NASTH 2019 Scientific Symposium are now published in Haemophilia, the official journal of HTRS. 

For more info, CLICK HERE.

 

Podcast: NHLBI Resources and Grants for Hematologists with Drs. DiMichele and Hoots

How to maximize research training and funding opportunities for non-malignant hematology and blood science investigators is the subject of this free podcast, in which Dr. Donna DiMichele and Dr. Keith Hoots of the National Heart, Lung, and Blood Institute (NHLBI) talk about NHLBI and National Institutes of Health resources and grants available to hematologists.  

For more info, CLICK HERE.


 

Apply for a Grant

Announcing the HTRS 2020 Mentored Research Award
Applications must be submitted at https://htrs.smapply.org after registering with your email and password.  Click on "Register" to begin.  (You will be able to save your work and return to it later.)

Pre-proposal Deadline has been extended to Friday, September 6, 2019 at 11:59 p.m. ET

.

THSNA Travel-to-a-Mentor Award

.

2019 HTRS Annual Business Meeting: June 10, 2019

HTRS members, please check your email for a link to register now!

 

The 2018 HTRS Annual Business Meeting webinar and slides are available to HTRS members for viewing in the members-only section on the HTRS website.

.

 

Join a Registry 

The Children’s Hospital-Acquired Thrombosis (CHAT) Study

 

 

World Thrombosis Day ("WTD") is Sunday, October 13

About 900,000 people in the U.S. alone are affected by blood clots each year, and about 100,000 of those will die -- greater than the total number of people who lose their lives each year to AIDS, breast cancer, and motor vehicle crashes combined.  Even more startling: around the world, one in four people worldwide are suffering and dying from conditions caused by thrombosis, according to the WTD website.

We would like to thank our HTRS member physician scientists, PhD investigators, thrombosis nurses, and all allied health professionals whose career passions revolve around advancing research and clinical treatment for patients with thrombosis.  Specially, we acknowledge HTRS Director Mary Cushman, MD, MSc, who recently helped moderate the World Thrombosis Day 2019 Webinar co-hosted by International Society on Thrombosis and Haemostasis (ISTH) and the Centers for Disease Control and Prevention (CDC).  The topic was "Top 3 Considerations for the Prevention of Hospital-Associated VTE."

If you'd like to join the WTD movement and/or find a local event taking place this Sunday, 10/13, visit www.worldthrombosisday.org/action/partners.

To stay informed, CLICK HERE.

Announcing 2020 HTRS/Novo Nordisk Clinical Fellowship Award (CFA) in Hemophilia and Rare Bleeding Disorders

HTRS and Novo Nordisk Inc. announce the availability of one Clinical Fellowship Award (CFA) in 2020 focused on hemophilia and rare bleeding disorders for one academic year (July 1, 2020 - June 30, 2021). During the fellowship year, the awardee must be mentored by an experienced MD, MD/PhD or DO working in hemophilia or rare bleeding disorders at an established U.S.-based hemostasis treatment center (HTC).

The deadline is January 31, 2020, by 11:59 PM ET.  Submit applications via our new Online Grant Submission site: https://htrs.smapply.org. Please scroll to the bottom of the page for the HTRS/Novo Nordisk CFA Program, look to the right, and click on MORE.

For more details, see the Request for Proposals: CLICK HERE

The online Application Form is available HERE

This 2020 award is supported by an educational grant from Novo Nordisk Inc.

Earl W. Davie Symposium: November 2019, Vancouver

The University of British Columbia Centre for Blood Research presents the Earl W. Davie Symposium on November 13, 2019 in Vancouver, Canada. Trainee Travel/Accommodation Awards are available. 

For more information, CLICK HERE.

To register, CLICK HERE.

2020 HTRS Research Colloquium: Registration now open

Join us for our second biennial Research Colloquium, a dynamic meeting focused on professional development and networking in benign hematology for:

  • Basic Scientists
  • Translational Researchers
  • Clinicians/Physician-Scientists

Date and Location: April 21-22, 2020 at the Hyatt Regency Chicago

Travel Awards are available for residents, post-docs, fellows, instructors and junior faculty within seven years of completing fellowship.

READ MORE

For more info, visit the Colloquium website at https://www.eiseverywhere.com/website/4770/home/

 

SAVE THE DATES!

2020 HTRS Research Colloquium

April 21-22, 2020: Pre-THSNA 2020 Summit, Hyatt Regency, Chicago

The HTRS Research Colloquium targets junior faculty and early-stage investigators (MDs, DOs, MD/PhDs, and PhDs) who have completed fellowship and/or postdoctoral training and are working to build sustainable academic research careers in hemostasis and thrombosis. Third- or fourth-year medical fellows and/or postdocs may apply to attend if they can demonstrate an established commitment to building a research career in hemostasis or thrombosis upon completion of training. Travel awards are available for early-stage investigators upon application.

2020 THSNA Summit

April 22-25, 2020: Sheraton Hotel, Chicago IL

2021 HTRS Scientific Symposium

March 11-13, 2021: Loews Coronado Bay, San Diego, CA

 

HTRS/NASTH 2019 Scientific Symposium: For CME credits, attendees should use form and passcode 

On the last day of the meeting, attendees received the electronic form and passcode from the [email protected] email account twice following the meeting -- which are needed to get CME credits. For more info, contact [email protected] directly.

This was the 11th Symposium of the Hemostasis and Thrombosis Research Society (HTRS), and the first in which NASTH partnered with us.  Our organizations brought together leading basic and translational science investigators with clinical colleagues for a dynamic meeting featuring:

  • State-of-the-Art Lectures and Scientific Sessions
  • Collaboration and networking
  • Oral Abstract Presentations and Poster Sessions
  • Career Development Breakfasts for early career investigators

Thanks to the HTRS/NASTH 2019 Symposium Sponsors, Exhibitors, and Medical Education Supporters:

Sponsors
Bayer, BPL, Cincinnati Children's Hospital, CSL Behring, Genentech, HTRS Members who Donated to the 2018 Annual Appeal, Octapharma, Pfizer,  Sanofi Genzyme, Sebia, Takeda, Tremeau Pharmaceuticals, uniQure Inc.

Exhibitors
Alnylam Pharmaceuticals, Bayer, BioMarin Pharmaceutical, BMS/Pfizer, BPL, CSL Behring, CSL Behring Medical Affairs, Foundation for Women and Girls with Blood Disorders, Genentech, Grifols USA, LLC, Hemophilia Alliance, Kedrion Biopharma Inc., Machaon Diagnostics, Novo Nordisk Inc., Pfizer, Red Chip Enterprises, Sanofi Genzyme, Takeda, Takeda Medical Affairs, Tremeau Pharmaceuticals, Versiti

Medical Education Grants
Bayer, CSL Behring, Genentech, Grifols USA, Inc., Pfizer, Portola Pharmaceuticals, Inc.